3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
16
Breast Neoplasms
7
Urinary Bladder Neoplasms
4
Lung Neoplasms
4
Colorectal Neoplasms
4
Ovarian Neoplasms
3
Testicular Neoplasms
2
Triple Negative Breast Neoplasms
1
Rectal Neoplasms
1
Prostate Adenocarcinoma
1
Pancreatic Neoplasms
1
Overweight
1
Obesity
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Lymphoma
1
Kidney Neoplasms
1
Health Behavior
1
Erectile Dysfunction
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Breast Neoplasms, Male
1
Anxiety Disorders
1
Interventions
pembrolizumab
92
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
26
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Educational Status
×
Genitourinary
×
Clear all
NCT05154084
2023-11-14
RESECT
British Urology Researchers in Surgical Training
Completed
19,505 enrolled